The chief executive of generic drugmaker Sandoz said a proposal by the CEOs of Novartis and Sanofi to introduce a Europe-wide list price for new medicines is "deeply flawed" and would not solve global ...

Sandoz (OTCQX:SDZXF), which was spun out of Swiss pharma giant Novartis (NVS ... and its lawsuit comes as the company seeks the product’s U.S. launch. Indicated for inflammatory diseases ...

Sandoz already markets six respiratory products, with almost a dozen in ... From AAPS 2025, an interview with Dr Dhaval Shah, professor of pharmaceutical sciences at the University of Buffalo ...

Despite battling for AMD market share against products from rivals Biocon ... South Africa-based Aspen Pharmaceuticals bought ...

Generics maker Sandoz says president should focus on tactic of ‘evergreening’ pricier products in his drive to lower costs ...

The corporate defendants are Sandoz Inc., Actavis Holdco U.S. Inc., Actavis Elizabeth LLC, Actavis Pharma Inc., Amneal Pharmaceuticals ... affordable generic products to consumers. Perrigo’s Core ...

SteinCares serves as a bridge between pharmaceutical companies ... to market with many biosimilars and generic products, we were selected by Sandoz to do this transaction in Colombia,” he ...

Sandoz dials up product launch plans ahead of market debut Sandoz plans to launch at least five additional biologic drugs, its CEO Richard Saynor said, as the generics drugs business of ...

Under the terms of the agreement, Sandoz has exclusive commercial rights for a biosimilar of ipilimumab in Australia, Canada, Europe, Japan and the US. The core sequence patent for ipilimumab ...

Good morning, ladies and gentlemen, and welcome to the Sandoz call today. I will now pass on to Craig Marks, Head of Investor Relations, for his opening remarks. Thank you. Welcome to the Sandoz Q1 ...

While Trump had initially exempted pharmaceuticals from ... reflecting enhanced product mix and operational efficiencies. Looking ahead, Sandoz expects continued momentum in 2025, with plans ...